BRIDGEWATER, N.J., March 27, 2019 /PRNewswire/ -- Insmed
Incorporated (Nasdaq: INSM), a global biopharmaceutical company on
a mission to transform the lives of patients with serious and rare
diseases, today announced that Paolo
Tombesi, Chief Financial Officer, will be leaving the
company effective June 2, 2019, and
will thereafter remain available on a consulting basis. A
search is under way for a new Chief Financial Officer.
Insmed also announced the promotion of John Goll to Chief Accounting Officer, effective
immediately.
"On behalf of the Company and the Board we want to thank Paolo
for his many contributions to Insmed over the past two years," said
Will Lewis, Chairman and Chief
Executive Officer of Insmed. "We wish Paolo continued success
in his future endeavors. I also want to congratulate John on
his promotion."
Mr. Tombesi's departure is not the result of any dispute or
disagreement with the Company including any matters relating to the
Company's accounting practices or financial reporting.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is
ARIKAYCE® (amikacin liposome inhalation
suspension), which is approved in the
United States for the treatment of Mycobacterium
avium complex (MAC) lung disease as part of a combination
antibacterial drug regimen for adult patients with limited or no
alternative treatment options. MAC lung disease is a rare and
often chronic infection that can cause irreversible lung damage and
can be fatal. Insmed's earlier-stage clinical pipeline
includes INS1007, a novel oral reversible inhibitor of dipeptidyl
peptidase 1 with therapeutic potential in non-cystic fibrosis
bronchiectasis and other inflammatory diseases, and INS1009, an
inhaled formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more
information, visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-announces-management-changes-300819594.html
SOURCE Insmed Incorporated